Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 15/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 15/20 | 0.36 |
| ▸ | SLC2A4 | P14672 | 15/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 6/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503751 | 0.93 | EPAS1 (0.38) | EPAS1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL16503752 | 0.92 | SLC2A1 (0.41) | EPAS1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL16503753 | 0.92 | EPAS1 (0.41) | EPAS1NPC1HPGDRAB9AL3MBTL1 | |
| SCHEMBL16503763 | 0.92 | EPAS1 (0.37) | EPAS1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL16572256 | 0.88 | EPAS1 (0.35) | EPAS1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL16503737 | 0.85 | HPGD (0.36) | EPAS1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL1696948 | 0.85 | EPAS1 (0.42) | EPAS1NTRK1PDE4APDE4BPDE4C | |
| SCHEMBL16503738 | 0.83 | EPAS1 (0.44) | EPAS1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL16503748 | 0.83 | EPAS1 (0.41) | EPAS1NTRK1PDE4APDE4BPDE4C | |
| SCHEMBL16503722 | 0.83 | SLC2A1 (0.35) | SLC2A1SLC2A3SLC2A4SLC2A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980886-B2 | Anthranilic acid derivatives | BAYER CROPSCIENCE AG (DE) | 2015-03-17 | — | — | US | disclosed |
| US-8980886-B2 | Anthranilic acid derivatives | BAYER CROPSCIENCE AG (DE) | 2015-03-17 | — | — | US | disclosed |
| US-20110312953-A1 | ANTHRANILIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312953-A1 | ANTHRANILIC ACID DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312953-A1 | ANTHRANILIC ACID DERIVATIVES | ANTXR2, NQO2, ACLY | EPAS1 3339/4885SLC2A1 4190/4885SLC2A3 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.